title: [State of the art and therapeutic prospects in neuroectodermal tumours and other neuroendocrine pathologies].
abstract: The clinical and biological characteristics of neuroectodermal tumours (NETs) are such that their treatment is necessarily multidisciplinary. Surgery is the first therapeutic choice given that it is the only potentially curative treatment for this type of neoplasm. Medical treatment is mainly indicated in the treatment of metastatic disease and must be separated into three basic options: chemotherapy, immunotheraphy and hormone treatment. Owing to the low proliferative index generally found in NETs, chemotherapy is not very effective as a means of controlling tumour growth. Data in the literature on interferon suggest that it plays a limited role in the treatment of NETs, as do the preliminary results from studies on the association of interferon + chemotherapy. The introduction of somatostatin analogs in clinical practice represents an effective tool in the therapeutic strategy for NETs and has opened new possibilities for the management of other neoplasms. One particularly interesting aspect of the octreotide-mediated antitumour action concerns the blocking of tumour neo-angiogenesis. The majority of non-endocrine tumours also express specific somatostatin receptors and in theory it is possible to hypothesise an antiproliferative action also in tumours without these receptors mediated by the indirect antiproliferative effects of somatostatin.
authors.affiliation: Divisione di Oncologia Medica, AORN A. Cardarelli, Naples, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Guida
authors.forename: V
authors.initials: V
authors.lastname: Belsito Petrizzi
authors.forename: R
authors.initials: R
authors.lastname: Fiorentino
authors.forename: D
authors.initials: D
authors.lastname: Germano
authors.forename: R
authors.initials: R
authors.lastname: Guardasi
authors.forename: M L
authors.initials: ML
authors.lastname: Lentini-Graziano
authors.forename: G
authors.initials: G
authors.lastname: Cartenì
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D017599:Neuroectodermal Tumors / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents
vernacular_title: Attualità e prospettive terapeutiche nei tumori neuroectodermici e nelle altre patologie neuroendocrine.